Diagnostic Criteria Recommendations for Acute-on-Chronic Liver Failure Caused by Combination of Hepatitis B Virus and Alcohol
Hongqin Xu(Jilin University), Yanhang Gao(Jilin University), Yi Zhou(Shandong Provincial Hospital), Yubao Zheng(Sun Yat-sen University), Junqi Niu(Jilin University), Huadong Yan(Zhejiang Shuren University), Guohong Deng(University of Groningen), Xinyi Zhou(Shanghai Medical College of Fudan University), Xiaobo Lu(Xinjiang Medical University), Qun Zhang(Union Hospital), Zhongji Meng(Hubei University of Medicine), Shuning Sun(Beijing Tongren Hospital), Weituo Zhang(Tongren Hospital), Ruochan Chen(Central South University), Wenting Tan(Army Medical University), Yixin Hou(Wuhan National Laboratory for Optoelectronics), Guotao Zhong(Nanfang Hospital), Beiling Li(Key Laboratory of Guangdong Province), Xin Zheng(Union Hospital), Yu Shi(National Clinical Research Center for Digestive Diseases), Sen Luo(Hubei University of Medicine), Jing Liu(Sichuan University), Haiyu Wang(Jilin University), Feng Liu(Peking University), Hai Li(Shanghai Jiao Tong University), Yuanyuan Chen(Jahra Hospital), Tao Li(Yangtze University), Yan Zhang(Sichuan Provincial Hospital of Traditional Chinese Medicine), Yan Xiong, Wen Gu(University Hospital Münster), Liang Qiao(Shanghai Jiao Tong University), Jinming Zhao(Guangxi Medical University), Xiaoyu Wen(Jilin University), Jing Li(Capital Medical University), Xianbo Wang(Capital Medical University), Jinjun Chen(Southern Medical University), Min Zhang(Central South University), Zhiping Qian(Shanghai Public Health Clinical Center), Yan Huang(Central South University), Rongjiong Zheng(Xinjiang Medical University), Xiuhua Jiang(Key Laboratory of Guangdong Province), Haotang Ren(National Clinical Research Center for Digestive Diseases), Jiang Chang(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 0
Related Papers
The mechanism of HMGB1 secretion and release
|Experimental & Molecular Medicine|2022|793
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346